Table 3.
Most common grades 1 to 4 adverse events of chemotherapy and adverse events of special interest to simvastatin.
| Adverse events n (%) | Chemotherapy + simvastatin (n = 40) | Chemotherapy + placebo (n = 40) | ||
|---|---|---|---|---|
| Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | |
| Anemia | 34 (85) | 8 (20) | 32 (80) | 8 (20) |
| Thrombopenia | 5 (12.5) | 1 (2.5) | 4 (10) | 2 (5) |
| Neutropenia | 22 (55) | 12 (30) | 18 (45) | 16 (40) |
| Clinical hemorrhage | — | — | 1 (2.5) | — |
| Injection site reaction | 7 (17.5) | — | 5 (12.5) | — |
| Rash | — | — | 1 (2.5) | — |
| Left ventricle function | 1 (2.5) | — | — | 1 (2.5) |
| Stomatitis | — | — | 1 (2.5) | — |
| Creatinine elevation | 6 (15) | — | 5 (12.5) | — |
| Simvastatin special adverse events | — | |||
| ALT elevation∗ | 12 (30) | — | 13 (32.5) | — |
| CK elevation# | 1 (2.5) | — | 4 (10) | — |
∗None of the elevated levels of ALT exceed more than 3 times the upper limit of the reference range. #None of the elevated levels of CK exceed more than 5 times the upper limit of the reference ranges P value >>0.05 for all comparisons